Adult-onset dystonia

Handbook of Clinical Neurology

Volumn 100, Issue , 2011, Pages 481-511

  Evatt, Marian L ^a,b   Freeman, Alan ^a   Factor, Stewart ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOOK; DYSTONIA; HISTORY; HUMAN; ONSET AGE;

AGE OF ONSET; DYSTONIA; HISTORY, 16TH CENTURY; HUMANS;

EID: 79954467866     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52014-2.00037-9     Document Type: Book

References (302)

1. Adams S.G., Hunt E.J., Charles D.A., et al. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results. J Otolaryngol 1993, 22:171-175.
2. Adler C.H., Zimmerman R.S., Lyons M.K., et al. Perioperative use of botulinum toxin for movement disorder-induced cervical spine disease. Mov Disord 1996, 11:79-81.
3. Adler C.H., Factor S.A., Brin M., et al. Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia. Mov Disord 2002, 17:158-161.
4. Adler C.H., Bansberg S.F., Krein-Jones K., et al. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia. Mov Disord 2004, 19:1075-1079.
5. Alm P.A. Stuttering and the basal ganglia circuits: a critical review of possible relations. J Commun Disord 2004, 37:325-369.
6. Almasy L., Bressman S., De Leon D., et al. Ethnic variation in the clinical expression of idiopathic torsion dystonia. Mov Disord 1997, 12:715-721.
7. Almasy L., Bressman S.B., Raymond D., et al. Idiopathic torsion dystonia linked to chromosome 8 in two Mennonite families. Ann Neurol 1997, 42:670-673.
8. Altrocchi P.H., Forno L.S. Spontaneous oral-facial dyskinesia: neuropathology of a case. Neurology 1983, 33:802-805.
9. Aramideh M., Ongerboer De Visser B.W., Holstege G., et al. Blepharospasm in association with a lower pontine lesion. Neurology 1996, 46:476-478.
10. Aronson A.E., Brown J.R., Litin E.M., et al. Spastic dysphonia. I. Voice, neurologic, and psychiatric aspects. J Speech Hear Disord 1968, 33:203-218.
11. Aronson A.E., Brown J.R., Litin E.M., et al. Spastic dysphonia. II. Comparison with essential (voice) tremor and other neurologic and psychogenic dysphonias. J Speech Hear Disord 1968, 33:219-231.
12. Asgeirsson H., Jakobsson F., Hjaltason H., et al. Prevalence study of primary dystonia in Iceland. Mov Disord 2006, 21:293-298.
13. Baik J.S., Park J.H., Kim J.Y. Primary lingual dystonia induced by speaking. Mov Disord 2004, 19:1251-1252.
14. Baker R.S., Andersen A.H., Morecraft R.J., et al. A functional magnetic resonance imaging study in patients with benign essential blepharospasm. J Neuroophthalmol 2003, 23:11-15.
15. Balash Y., Giladi N. Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol 2004, 11:361-370.
16. Balasubramaniam R., Rasmussen J., Carlson L.W., et al. Oromandibular dystonia revisited: a review and a unique case. J Oral Maxillofac Surg 2008, 66:379-386.
17. Bara-Jimenez W., Shelton P., et al. Spatial discrimination is abnormal in focal hand dystonia. Neurology 2000, 55:1869-1873.
18. Barnes M.P., Best D., Kidd L., et al. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A - initial experiences. Eur J Neurol 2005, 12:947-955.
19. Benecke R., Jost W.H., Kanovsky P., et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005, 64:1949-1951.
20. Bentivoglio A.R., Daniele A., Albanese A., et al. Analysis of blink rate in patients with blepharospasm. Mov Disord 2006, 21:1225-1229.
21. Berardelli A., Curra A. Pathophysiology and treatment of cranial dystonia. Mov Disord 2002, 17:S70-S74.
22. Berardelli A., Rothwell J.C., Hallett M., et al. The pathophysiology of primary dystonia. Brain 1998, 121:1195-1212.
23. Bereznai B., Steude U., Seelos K., et al. Chronic high-frequency globus pallidus internus stimulation in different types of dystonia: a clinical, video, and MRI report of six patients presenting with segmental, cervical, and generalized dystonia. Mov Disord 2002, 17:138-144.
24. Berke G.S., Blackwell K.E., Gerratt B.R., et al. Selective laryngeal adductor denervation-reinnervation: a new surgical treatment for adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 1999, 108:227-231.
25. Berman B., Seeberger L., Kumar R. Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia. Mov Disord 2005, 20:233-237.
26. Bertrand C.M. Selective peripheral denervation for spasmodic torticollis: surgical technique, results, and observations in 260 cases. Surg Neurol 1993, 40:96-103.
27. Bertrand C.M., Molina-Negro P. Selective peripheral denervation in 111 cases of spasmodic torticollis: rationale and results. Adv Neurol 1988, 50:637-643.
28. Bertrand C., Molina-Negro P., Bouvier G., et al. Observations and analysis of results in 131 cases of spasmodic torticollis after selective denervation. Appl Neurophysiol 1987, 50:319-323.
29. Bhatia K., Daniel S.E., Marsden C.D. Orofacial dystonia and rest tremor in a patient with normal brain pathology. Mov Disord 1993, 8:361-362.
30. Bhattacharyya N., Tarsy D. Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia. Arch Otolaryngol Head Neck Surg 2001, 127:389-392.
31. Bhidayasiri R., Jen J.C., Baloh R.W. Three brothers with a very-late-onset writer's cramp. Mov Disord 2005, 20:1375-1377.
32. Bhidayasiri R., Cardoso F., Truong D.D. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur J Neurol 2006, 13:21-29.
33. Bittar R.G., Yianni J., Wang S., et al. Deep brain stimulation for generalised dystonia and spasmodic torticollis. J Clin Neurosci 2005, 12:12-16.
34. Black K.J., Ongur D., Perlmutter J.S. Putamen volume in idiopathic focal dystonia. Neurology 1998, 51:819-824.
35. Blitzer A., Lovelace R.E., Brin M.F., et al. Electromyographic findings in focal laryngeal dystonia (spastic dysphonia). Ann Otol Rhinol Laryngol 1985, 94:591-594.
36. Blitzer A., Brin M.F., Fahn S., et al. Botulinum toxin (BOTOX) for the treatment of " spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope 1986, 96:1300-1301.
37. Blitzer A., Brin M.F., Fahn S., et al. Clinical and laboratory characteristics of focal laryngeal dystonia: study of 110 cases. Laryngoscope 1988, 98:636-640.
38. Blitzer A., Brin M.F., Greene P.E., et al. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 1989, 98:93-97.
39. Blitzer A., Brin M.F., Stewart C.F. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1998, 108:1435-1441.
40. Blomstedt P., Tisch S., Hariz M.I. Pallidal deep brain stimulation in the treatment of Meige syndrome. Acta Neurol Scand 2008, 118:198-202.
41. Bradley E.A., Hodge D.O., Bartley G.B. Benign essential blepharospasm among residents of Olmsted County, Minnesota, 1976 to 1995: an epidemiologic study. Ophthal Plast Reconstr Surg 2003, 19:177-181.
42. Brans J.W., Lindeboom R., Snoek J.W., et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996, 46:1066-1072.
43. Brashear A., Lew M.F., Dykstra D.D., et al. Safety and efficacy of neurobloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999, 53:1439-1446.
44. Braun V., Richter H.P. Selective peripheral denervation for spasmodic torticollis: 13-year experience with 155 patients. J Neurosurg 2002, 97:207-212.
45. Brin M.F., Fahn S., Moskowitz C., et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987, 2:237-254.
46. Brin M.F., Blitzer A., Fahn S., et al. Adductor laryngeal dystonia (spastic dysphonia): treatment with local injections of botulinum toxin (Botox). Mov Disord 1989, 4:287-296.
47. Brin M.F., Lew M.F., Adler C.H., et al. Safety and efficacy of neurobloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999, 53:1431-1438.
48. Burbaud P., Guehl D., Lagueny A., et al. A pilot trial of clozapine in the treatment of cervical dystonia. J Neurol 1998, 245:329-331.
49. Burke R.E., Fahn S., Marsden C.D. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986, 36:160-164.
50. Butler A.G., Duffey P.O., Hawthorne M.R., et al. An epidemiologic survey of dystonia within the entire population of northeast England over the past nine years. Adv Neurol 2004, 94:95-99.
51. Byl N.N., Merzenich M.M., Jenkins W.M. A primate genesis model of focal dystonia and repetitive strain injury: I. Learning-induced dedifferentiation of the representation of the hand in the primary somatosensory cortex in adult monkeys. Neurology 1996, 47:508-520.
52. Byl N.N., Nagajaran S., Mckenzie A.L. Effect of sensory discrimination training on structure and function in patients with focal hand dystonia: a case series. Arch Phys Med Rehabil 2003, 84:1505-1514.
53. Calace P., Cortese G., Piscopo R., et al. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur J Ophthalmol 2003, 13:331-336.
54. Capelle H.H., Weigel R., Krauss J.K. Bilateral pallidal stimulation for blepharospasm-oromandibular dystonia (Meige syndrome). Neurology 2003, 60:2017-2018.
55. Castelbuono A., Miller N.R. Spontaneous remission in patients with essential blepharospasm and Meige syndrome. Am J Ophthalmol 1998, 126:432-435.
56. Castelon Konkiewitz E., Trender-Gerhard I., Kamm C., et al. Service-based survey of dystonia in Munich. Neuroepidemiology 2002, 21:202-206.
57. Chan J., Brin M.F., Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991, 6:119-126.
58. Chapman K.L., Bartley G.B., Waller R.R., et al. Follow-up of patients with essential blepharospasm who underwent eyelid protractor myectomy at the Mayo Clinic from 1980 through 1995. Ophthal Plast Reconstr Surg 1999, 15:106-110.
59. Charles P.D., Davis T.L., Shannon K.M., et al. Tongue protrusion dystonia: treatment with botulinum toxin. South Med J 1997, 90:522-525.
60. Charness M.E., Ross M.H., Shefner J.M. Ulnar neuropathy and dystonic flexion of the fourth and fifth digits: clinical correlation in musicians. Muscle Nerve 1996, 19:431-437.
61. Chen R.S., Tsai C.H., Lu C.S. Reciprocal inhibition in writer's cramp. Mov Disord 1995, 10:556-561.
62. Chen X., Ma A., Liang J., Ji S., et al. Selective denervation and resection of cervical muscles in the treatment of spasmodic torticollis: long-term follow-up results in 207 cases. Stereotact Funct Neurosurg 2000, 75:96-102.
63. Chhetri D.K., Merati A.L., Blumin J.H., et al. Reliability of the perceptual evaluation of adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 2008, 117:159-165.
64. Clarimon J., Brancati F., Peckham E., et al. Assessing the role of DRD5 and DYT1 in two different case-control series with primary blepharospasm. Mov Disord 2007, 22:162-166.
65. Clark G.T. The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin. Phys Med Rehabil Clin N Am 2003, 14:727-748.
66. Claypool D.W., Duane D.D., Ilstrup D.M., et al. Epidemiology and outcome of cervical dystonia (spasmodic torticollis) in Rochester, Minnesota. Mov Disord 1995, 10:608-614.
67. Cohen-Gadol A.A., Ahlskog J.E., Matsumoto J.Y., et al. Selective peripheral denervation for the treatment of intractable spasmodic torticollis: experience with 168 patients at the Mayo Clinic. J Neurosurg 2003, 98:1247-1254.
68. Cohen L.G., Hallett M. Hand cramps: clinical features and electromyographic patterns in a focal dystonia. Neurology 1988, 38:1005-1012.
69. Cole R., Hallett M., Cohen L.G. Double-blind trial of botulinum toxin for treatment of focal hand dystonia. Mov Disord 1995, 10:466-471.
70. Colosimo C., Chianese M., Giovannelli M., et al. Botulinum toxin type B in blepharospasm and hemifacial spasm. J Neurol Neurosurg Psychiatry 2003, 74:687.
71. Comella C.L., Jankovic J., Shannon K.M., et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005, 65:1423-1429.
72. Courey M.S., Garrett C.G., Billante C.R., et al. Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. Ann Otol Rhinol Laryngol 2000, 109:819-822.
73. Critchley M. Spastic dysphonia " inspiratory speech" Brain 1939, 62:96-103.
74. Damrose J.F., Goldman S.N., Groessl E.J., et al. The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia. J Voice 2004, 18:415-422.
75. Das S.K., Banerjee T.K., Biswas A., et al. Community survey of primary dystonia in the city of Kolkata, India. Mov Disord 2007, 22:2031-2036.
76. Dauer W.T., Burke R.E., Greene P., et al. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain 1998, 121:547-560.
77. Defazio G., Berardelli A., Abbruzzese G., et al. Risk factors for spread of primary adult onset blepharospasm: a multicentre investigation of the Italian movement disorders study group. J Neurol Neurosurg Psychiatry 1999, 67:613-619.
78. Defazio G., Brancati F., Valente E.M., et al. Familial blepharospasm is inherited as an autosomal dominant trait and relates to a novel unassigned gene. Mov Disord 2003, 18:207-212.
79. Defazio G., Abbruzzese G., Livrea P., et al. Epidemiology of primary dystonia. Lancet Neurol 2004, 3:673-678.
80. Defazio G., Martino D., Aniello M.S., et al. A family study on primary blepharospasm. J Neurol Neurosurg Psychiatry 2006, 77:252-254.
81. Delmaire C., Vidailhet M., Elbaz A., et al. Structural abnormalities in the cerebellum and sensorimotor circuit in writer's cramp. Neurology 2007, 69:376-380.
82. Dhaenens C.M., Krystkowiak P., Douay X., et al. Clinical and genetic evaluation in a French population presenting with primary focal dystonia. Mov Disord 2005, 20:822-825.
83. Draganski B., Thun-Hohenstein C., Bogdahn U., et al. " Motor circuit" gray matter changes in idiopathic cervical dystonia. Neurology 2003, 61:1228-1231.
84. Dresel C., Haslinger B., Castrop F., et al. Silent event-related fMRI reveals deficient motor and enhanced somatosensory activation in orofacial dystonia. Brain 2006, 129:36-46.
85. Duffey P.O., Butler A.G., Hawthorne M.R., et al. The epidemiology of the primary dystonias in the north of England. Adv Neurol 1998, 78:121-125.
86. Dutton J.J., Buckley E.G. Botulinum toxin in the management of blepharospasm. Arch Neurol 1986, 43:380-382.
87. Dutton J.J., White J.J., Richard M.J. Myobloc for the treatment of benign essential blepharospasm in patients refractory to botox. Ophthal Plast Reconstr Surg 2006, 22:173-177.
88. Dykstra D.D., Mendez A., Chappuis D., et al. Treatment of cervical dystonia and focal hand dystonia by high cervical continuously infused intrathecal baclofen: a report of 2 cases. Arch Phys Med Rehabil 2005, 86:830-833.
89. Epidemiological Study of Dystonia in Europe (ESDE) Collaborative GROUP A prevalence study of primary dystonia in eight European countries. J Neurol 2000, 247:787-792.
90. Erjanti H., Marttila R., Rinne U. The prevalence and incidence of cervical dystonia in south-western Finland. Mov Disord 1996, 11:A215.
91. Esmaeli-Gutstein B., Nahmias C., Thompson M., et al. Positron emission tomography in patients with benign essential blepharospasm. Ophthal Plast Reconstr Surg 1999, 15:23-27.
92. Esper C.D., Freeman A., Factor S.A. Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord 2010, 16:438-441.
93. Etgen T., Muhlau M., Gaser C., et al. Bilateral grey-matter increase in the putamen in primary blepharospasm. J Neurol Neurosurg Psychiatry 2006, 77:1017-1020.
94. Factor S.A., Barron K.D. Mosaic pattern of gliosis in the neostriatum of a North American man with craniocervical dystonia and parkinsonism. Mov Disord 1997, 12:783-789.
95. Factor S.A., Podskalny G.D., Molho E.S. Psychogenic movement disorders: frequency, clinical profile, and characteristics. J Neurol Neurosurg Psychiatry 1995, 59:406-412.
96. Fahn S. High dosage anticholinergic therapy in dystonia. Neurology 1983, 33:1255-1261.
97. Fahn S. Treatment of tardive dyskinesia: use of dopamine-depleting agents. Clin Neuropharmacol 1983, 6:151-158.
98. Filipovic S.R., Jahanshahi M., Viswanathan R., et al. Clinical features of the geste antagoniste in cervical dystonia. Adv Neurol 2004, 94:191-201.
99. Fletcher N.A., Harding A.E., Marsden C.D. A case-control study of idiopathic torsion dystonia. Mov Disord 1991, 6:304-309.
100. Foote K.D., Sanchez J.C., Okun M.S. Staged deep brain stimulation for refractory craniofacial dystonia with blepharospasm: case report and physiology. Neurosurgery 2005, 56:E415. discussion E415.
101. Ford B. Pallidotomy for generalized dystonia. Adv Neurol 2004, 94:287-299.
102. Friedman A., Fahn S. Spontaneous remissions in spasmodic torticollis. Neurology 1986, 36:398-400.
103. Frucht S., Fahn S., Ford B., et al. A geste antagoniste device to treat jaw-closing dystonia. Mov Disord 1999, 14:883-886.
104. Frucht S.J., Fahn S., Greene P.E., et al. The natural history of embouchure dystonia. Mov Disord 2001, 16:899-906.
105. Frueh B.R., Felt D.P., Wojno T.H., et al. Treatment of blepharospasm with botulinum toxin. A preliminary report. Arch Ophthalmol 1984, 102:1464-1468.
106. Fukaya C., Katayama Y., Kano T., et al. Thalamic deep brain stimulation for writer's cramp. J Neurosurg 2007, 107:977-982.
107. Galardi G., Perani D., Grassi F., et al. Basal ganglia and thalamo-cortical hypermetabolism in patients with spasmodic torticollis. Acta Neurol Scand 1996, 94:172-176.
108. Garcia-Albea E., Franch O., Munoz D., et al. Brueghel's syndrome, report of a case with postmortem studies. J Neurol Neurosurg Psychiatry 1981, 44:437-440.
109. Garraux G., Bauer A., Hanakawa T., et al. Changes in brain anatomy in focal hand dystonia. Ann Neurol 2004, 55:736-739.
110. Georgescu D., Vagefi M.R., Mcmullan T.F., et al. Upper eyelid myectomy in blepharospasm with associated apraxia of lid opening. Am J Ophthalmol 2008, 145:541-547.
111. Ghika J., Regli F., Growdon J.H. Sensory symptoms in cranial dystonia: a potential role in the etiology?. J Neurol Sci 1993, 116:142-147.
112. Gibb W.R., Lees A.J., Marsden C.D. Pathological report of four patients presenting with cranial dystonias. Mov Disord 1988, 3:211-221.
113. Gibb W.R., Kilford L., Marsden C.D. Severe generalised dystonia associated with a mosaic pattern of striatal gliosis. Mov Disord 1992, 7:217-223.
114. Gilbert G.J. Brueghel syndrome: its distinction from Meige syndrome. Neurology 1996, 46:1767-1769.
115. Gomez-Wong E., Marti M.J., Cossu G., et al. The 'geste antagonistique' induces transient modulation of the blink reflex in human patients with blepharospasm. Neurosci Lett 1998, 251:125-128.
116. Goto S., Shimazu H., Matsuzaki K., et al. Thalamic Vo-complex vs pallidal deep brain stimulation for focal hand dystonia. Neurology 2008, 70:1500-1501.
117. Grandas F., Elston J., Quinn N., et al. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 1988, 51:767-772.
118. Green J., Factor S.A. Nonmotor symptoms in dystonia. Handbook of Dystonia 2007, Informa Healthcare, New York. M. Stacy (Ed.).
119. Greene P. Baclofen in the treatment of dystonia. Clin Neuropharmacol 1992, 15:276-288.
120. Greene P., Shale H., Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 1988, 3:46-60.
121. Greene P., Shale H., Fahn S. Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. Adv Neurol 1988, 50:547-556.
122. Greene P., Kang U., Fahn S., et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990, 40:1213-1218.
123. Gundel H., Busch R., Ceballos-Baumann A., et al. Psychiatric comorbidity in patients with spasmodic dysphonia: a controlled study. J Neurol Neurosurg Psychiatry 2007, 78:1398-1400.
124. Hagenah J.M., Zuhlke C., Hellenbroich Y., et al. Focal dystonia as a presenting sign of spinocerebellar ataxia 17. Mov Disord 2004, 19:217-220.
125. Hall T.A., Mcgwin G., Searcey K., et al. Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm. Arch Ophthalmol 2006, 124:116-119.
126. Hallett M. Is dystonia a sensory disorder?. Ann Neurol 1995, 38:139-140.
127. Hallett M. Blepharospasm: recent advances. Neurology 2002, 59:1306-1312.
128. Hallett M. Pathophysiology of writer's cramp. Hum Mov Sci 2006, 25:454-463.
129. Hallett M., Evinger C., Jankovic J., et al. Update on blepharospasm: report from the BEBRF International Workshop. Neurology 2008, 71:1275-1282.
130. Hallett M., Benecke R., Blitzer A., et al. Treatment of focal dystonias with botulinum neurotoxin. Toxicon 2009, 54:628-633.
131. Hogikyan N.D., Wodchis W.P., Spak C., et al. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia. J Voice 2001, 15:576-586.
132. Holden P.K., Vokes D.E., Taylor M.B., et al. Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 2007, 116:891-896.
133. Holton J.L., Schneider S.A., Ganesharajah T., et al. Neuropathology of primary adult-onset dystonia. Neurology 2008, 70:695-699.
134. Houser M., Waltz T. Meige syndrome and pallidal deep brain stimulation. Mov Disord 2005, 20:1203-1205.
135. Hsiung G.Y., Das S.K., Ranawaya R., et al. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002, 17:1288-1293.
136. Hutchinson M., Nakamura T., Moeller J.R., et al. The metabolic topography of essential blepharospasm: a focal dystonia with general implications. Neurology 2000, 55:673-677.
137. Ishii K., Tamaoka A., Shoji S. A case of primary focal lingual dystonia induced by speaking. Eur J Neurol 2001, 8:507.
138. Islekel S., Zileli M., Zileli B. Unilateral pallidal stimulation in cervical dystonia. Stereotact Funct Neurosurg 1999, 72:248-252.
139. Jahanshahi M., Marion M.H., Marsden C.D. Natural history of adult-onset idiopathic torticollis. Arch Neurol 1990, 47:548-552.
140. Jankovic J. Blepharospasm with basal ganglia lesions. Arch Neurol 1986, 43:866-868.
141. Jankovic J. Medical therapy and botulinum toxin in dystonia. Adv Neurol 1998, 78:169-183.
142. Jankovic J. Can peripheral trauma induce dystonia and other movement disorders? Yes!. Mov Disord 2001, 16:7-12.
143. Jankovic J., Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997, 48:358-362.
144. Jankovic J., Ford J. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 1983, 13:402-411.
145. Jankovic J., Nutt J.G. Blepharospasm and cranial-cervical dystonia (Meige's syndrome): familial occurrence. Adv Neurol 1988, 49:117-123.
146. Jankovic J., Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987, 37:616-623.
147. Jankovic J., Patel S.C. Blepharospasm associated with brainstem lesions. Neurology 1983, 33:1237-1240.
148. Jankovic J., Schwartz K., Donovan D.T. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990, 53:633-639.
149. Jankovic J., Leder S., Warner D., et al. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991, 41:1088-1091.
150. Jedynak P.C., Tranchant C., De Beyl D.Z. Prospective clinical study of writer's cramp. Mov Disord 2001, 16:494-499.
151. Jinnah H.A., Hess E.J. Experimental therapeutics for dystonia. Neurotherapeutics 2008, 5:198-209.
152. Jost W.H., Kohl A., Brinkmann S., et al. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm 2005, 112:905-913.
153. Jost W.H., Blumel J., Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 2007, 67:669-683.
154. Junker J., Oberwittler C., Jackson D., et al. Utilization and perceived effectiveness of complementary and alternative medicine in patients with dystonia. Mov Disord 2004, 19:158-161.
155. Kaji R., Rothwell J.C., Katayama M., et al. Tonic vibration reflex and muscle afferent block in writer's cramp. Ann Neurol 1995, 38:155-162.
156. Kamm C., Naumann M., Mueller J., et al. The DYT1 GAG deletion is infrequent in sporadic and familial writer' s cramp. Mov Disord 2000, 15:1238-1241.
157. Kandil M.R., Tohamy S.A., Fattah M.A., et al. Prevalence of chorea, dystonia and athetosis in Assiut, Egypt: a clinical and epidemiological study. Neuroepidemiology 1994, 13:202-210.
158. Kang U.J., Burke R.E., Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986, 1:193-208.
159. Karp B.I. Botulinum toxin treatment of occupational and focal hand dystonia. Mov Disord 2004, 19:S116-S119.
160. Karp B.I., Goldstein S.R., Chen R., et al. An open trial of clozapine for dystonia. Mov Disord 1999, 14:652-657.
161. Kerrison J.B., Lancaster J.L., Zamarripa F.E., et al. Positron emission tomography scanning in essential blepharospasm. Am J Ophthalmol 2003, 136:846-852.
162. Kiss Z.H., Doig-Beyaert K., Eliasziw M., et al. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain 2007, 130:2879-2886.
163. Kiwak K.J., Deray M.J., Shields W.D. Torticollis in three children with syringomyelia and spinal cord tumor. Neurology 1983, 33:946-948.
164. Kiziltan G., Akalin M.A. Stuttering may be a type of action dystonia. Mov Disord 1996, 11:278-282.
165. Koriwchak M.J., Netterville J.L., Snowden T., et al. Alternating unilateral botulinum toxin type A (BOTOX) injections for spasmodic dysphonia. Laryngoscope 1996, 106:1476-1481.
166. Kraft S.P., Lang A.E. Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations. Can J Neurol Sci 1988, 15:276-280.
167. Krauss J.K., Yianni J., Loher T.J., et al. Deep brain stimulation for dystonia. J Clin Neurophysiol 2004, 21:18-30.
168. Kruisdijk J.J., Koelman J.H., Ongerboer De Visser B.W., et al. Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry 2007, 78:264-270.
169. Kulisevsky J., Marti M.J., Ferrer I., et al. Meige syndrome: neuropathology of a case. Mov Disord 1988, 3:170-175.
170. Kupsch A., Benecke R., Muller J., et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006, 355:1978-1990.
171. Kwak C.H., Jankovic J. Tourettism and dystonia after subcortical stroke. Mov Disord 2002, 17:821-825.
172. Lang A.E. Writing tremor and writing dystonia. Mov Disord 1990, 5:354-355.
173. Lang A.E. Psychogenic dystonia: a review of 18 cases. Can J Neurol Sci 1995, 22:136-143.
174. Lang A.E., Rogaeva E.A., Tsuda T., et al. Homozygous inheritance of the Machado-Joseph disease gene. Ann Neurol 1994, 36:443-447.
175. Le K.D., Nilsen B., Dietrichs E. Prevalence of primary focal and segmental dystonia in Oslo. Neurology 2003, 61:1294-1296.
176. Ledoux M.S., Brady K.A. Secondary cervical dystonia associated with structural lesions of the central nervous system. Mov Disord 2003, 18:60-69.
177. Lenz F.A., Byl N.N. Reorganization in the cutaneous core of the human thalamic principal somatic sensory nucleus (Ventral caudal) in patients with dystonia. J Neurophysiol 1999, 82:3204-3212.
178. Lerner A., Shill H., Hanakawa T., et al. Regional cerebral blood flow correlates of the severity of writer's cramp symptoms. Neuroimage 2004, 21:904-913.
179. Leube B., Rudnicki D., Ratzlaff T., et al. Idiopathic torsion dystonia: assignment of a gene to chromosome 18p in a German family with adult onset, autosomal dominant inheritance and purely focal distribution. Hum Mol Genet 1996, 5:1673-1677.
180. Leube B., Hendgen T., Kessler K.R., et al. Evidence for DYT7 being a common cause of cervical dystonia (torticollis) in Central Europe. Am J Med Genet 1997, 74:529-532.
181. Leube B., Hendgen T., Kessler K.R., et al. Sporadic focal dystonia in northwest Germany: molecular basis on chromosome 18p. Ann Neurol 1997, 42:111-114.
182. Leube B., Kessler K.R., Goecke T., et al. Frequency of familial inheritance among 488 index patients with idiopathic focal dystonia and clinical variability in a large family. Mov Disord 1997, 12:1000-1006.
183. Lew M.F., Adornato B.T., Duane D.D., et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997, 49:701-707.
184. Li S.C., Schoenberg B.S., Wang C.C., et al. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol 1985, 42:655-657.
185. Lo S.E., Gelb M., Frucht S.J. Geste antagonistes in idiopathic lower cranial dystonia. Mov Disord 2007, 22:1012-1017.
186. Lucetti C., Nuti A., Gambaccini G., et al. Mexiletine in the treatment of torticollis and generalized dystonia. Clin Neuropharmacol 2000, 23:186-189.
187. Marchetti A., Magar R., Findley L., et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 2005, 20:937-944.
188. Marion M.H., Klap P., Perrin A., et al. Stridor and focal laryngeal dystonia. Lancet 1992, 339:457-458.
189. Mark M.H., Sage J.I., Dickson D.W., et al. Meige syndrome in the spectrum of Lewy body disease. Neurology 1994, 44:1432-1436.
190. Marras C., Van Den Eeden S.K., Fross R.D., et al. Minimum incidence of primary cervical dystonia in a multiethnic health care population. Neurology 2007, 69:676-680.
191. Marsden C.D. Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia?. J Neurol Neurosurg Psychiatry 1976, 39:1204-1209.
192. Marsden C.D., Sheehy M.P. Writer's cramp. Trends Neurosci 1990, 13:148-153.
193. Marsden C.D., Obeso J.A., Zarranz J.J., et al. The anatomical basis of symptomatic hemidystonia. Brain 1985, 108:463-483.
194. Martino D., Defazio G., Alessio G., et al. Relationship between eye symptoms and blepharospasm: a multicenter case-control study. Mov Disord 2005, 20:1564-1570.
195. Matsumoto S., Nishimura M., Shibasaki H., et al. Epidemiology of primary dystonias in Japan: comparison with Western countries. Mov Disord 2003, 18:1196-1198.
196. Mauriello J.A. Blepharospasm, Meige syndrome, and hemifacial spasm: treatment with botulinum toxin. Neurology 1985, 35:1499-1500.
197. McKenzie A.L., Nagarajan S.S., Roberts T.P., et al. Somatosensory representation of the digits and clinical performance in patients with focal hand dystonia. Am J Phys Med Rehabil 2003, 82:737-749.
198. McNaught K.S., Kapustin A., Jackson T., et al. Brainstem pathology in DYT1 primary torsion dystonia. Ann Neurol 2004, 56:540-547.
199. Meige H. Les convulsions de la face, une forme clinique de convulsion faciale bilateral et mediane. Rev Neurol 1910, 21:437-443.
200. Meyer T.K., Blitzer A. Spasmodic dysphonia. Handbook of Dystonia 2007, Informa Healthcare, New York. M. Stacy (Ed.).
201. Mink J.W. The basal ganglia and involuntary movements: impaired inhibition of competing motor patterns. Arch Neurol 2003, 60:1365-1368.
202. Misbahuddin A., Placzek M.R., Chaudhuri K.R., et al. A polymorphism in the dopamine receptor DRD5 is associated with blepharospasm. Neurology 2002, 58:124-126.
203. Modi G., Modi M., Martinus I., et al. The clinical and genetic characteristics of spinocerebellar ataxia type 7 (SCA 7) in three Black South African families. Acta Neurol Scand 2000, 101:177-182.
204. Molho E.S., Feustel P.J., Factor S.A. Clinical comparison of tardive and idiopathic cervical dystonia. Mov Disord 1998, 13:486-489.
205. Moller E., Bakke M., Dalager T., et al. Oromandibular dystonia involving the lateral pterygoid muscles: four cases with different complexity. Mov Disord 2007, 22:785-790.
206. Molloy F.M., Carr T.D., Zeuner K.E., et al. Abnormalities of spatial discrimination in focal and generalized dystonia. Brain 2003, 126:2175-2182.
207. Moro E., Piboolnurak P., Arenovich T., et al. Pallidal stimulation in cervical dystonia: clinical implications of acute changes in stimulation parameters. Eur J Neurol 2009, 16:506-512.
208. Muller J., Wissel J., Masuhr F., et al. Clinical characteristics of the geste antagoniste in cervical dystonia. J Neurol 2001, 248:478-482.
209. Muller J., Kemmler G., Wissel J., et al. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 2002, 249:842-846.
210. Muller J., Kiechl S., Wenning G.K., et al. The prevalence of primary dystonia in the general community. Neurology 2002, 59:941-943.
211. Muller J., Wenning G.K., Wissel J., et al. Riluzole therapy in cervical dystonia. Mov Disord 2002, 17:198-200.
212. Munchau A., Palmer J.D., Dressler D., et al. Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia. Brain 2001, 124:769-783.
213. Nair K.R. Associated blepharospasm in lower pontine lesions. Neurology 1997, 48:553.
214. Nakashima K., Kusumi M., Inoue Y., et al. Prevalence of focal dystonias in the western area of Tottori Prefecture in Japan. Mov Disord 1995, 10:440-443.
215. Nishioka G.J., Montgomery M.T. Masticatory muscle hyperactivity in temporomandibular disorders: is it an extrapyramidally expressed disorder?. J Am Dent Assoc 1988, 116:514-520.
216. Nussgens Z., Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997, 235:197-199.
217. Nutt J.G., Muenter M.D., Aronson A., et al. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988, 3:188-194.
218. Nutt J.G., Muenter M.D., Melton L.J., et al. Epidemiology of dystonia in Rochester, Minnesota. Adv Neurol 1988, 50:361-365.
219. Obermann M., Yaldizli O., De Greiff A., et al. Morphometric changes of sensorimotor structures in focal dystonia. Mov Disord 2007, 22:1117-1123.
220. Ochudlo S., Bryniarski P., Opala G. Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm. Parkinsonism Relat Disord 2007, 13:505-508.
221. Ohara S., Miki J., Momoi H., et al. Treatment of spasmodic torticollis with mexiletine: a case report. Mov Disord 1997, 12:466-469.
222. Ohara S., Hayashi R., Momoi H., et al. Mexiletine in the treatment of spasmodic torticollis. Mov Disord 1998, 13:934-940.
223. Ostrem J.L., Starr P.A. Treatment of dystonia with deep brain stimulation. Neurotherapeutics 2008, 5:320-330.
224. Ostrem J.L., Marks W.J., Volz M.M., et al. Pallidal deep brain stimulation in patients with cranial-cervical dystonia (Meige syndrome). Mov Disord 2007, 22:1885-1891.
225. Papapetropoulos S., Singer C. Eating dysfunction associated with oromandibular dystonia: clinical characteristics and treatment considerations. Head Face Med 2006, 2:47.
226. Papapetropoulos S., Singer C. Primary focal lingual dystonia. Mov Disord 2006, 21:429-430.
227. Parkes D., Schachter M. Meige, Brueghel or Black?. Neurology 1981, 31:498.
228. Park J.B., Simpson L.L., Anderson T.D., et al. Immunologic characterization of spasmodic dysphonia patients who develop resistance to botulinum toxin. J Voice 2003, 17:255-264.
229. Pekmezovic T., Svetel M., Ivanovic N., et al. Quality of life in patients with focal dystonia. Clin Neurol Neurosurg 2009, 111:161-164.
230. Perlmutter J.S., Stambuk M.K., Markham J., et al. Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci 1997, 17:843-850.
231. Poewe W., Deuschl G., Nebe A., et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 1998, 64:13-17.
232. Pohl C., Happe J., Klockgether T. Cooling improves the writing performance of patients with writer's cramp. Mov Disord 2002, 17:1341-1344.
233. Priori A., Pesenti A., Cappellari A., et al. Limb immobilization for the treatment of focal occupational dystonia. Neurology 2001, 57:405-409.
234. Pullman S.L., Greene P., Fahn S., et al. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol 1996, 53:617-624.
235. Quartarone A., Bagnato S., Rizzo V., et al. Abnormal associative plasticity of the human motor cortex in writer's cramp. Brain 2003, 126:2586-2596.
236. Quartarone A., Sant'angelo A., Battaglia F., et al. Enhanced long-term potentiation-like plasticity of the trigeminal blink reflex circuit in blepharospasm. J Neurosci 2006, 26:716-721.
237. Raffaele R., Patti F., Sciacca A., et al. Effects of short-term reserpine treatment on generalized and focal dystonic-dyskinetic syndromes. Funct Neurol 1988, 3:327-335.
238. Raudino F. Is temporomandibular dysfunction a cranial dystonia? An electrophysiological study. Headache 1994, 34:471-475.
239. Reimer J., Gilg K., Karow A., et al. Health-related quality of life in blepharospasm or hemifacial spasm. Acta Neurol Scand 2005, 111:64-70.
240. Rieder C.R., Schestatsky P., Socal M.P., et al. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol 2007, 30:39-42.
241. Robinson R., Mccarthy G.T., Bandmann O., et al. GTP cyclohydrolase deficiency; intrafamilial variation in clinical phenotype, including levodopa responsiveness. J Neurol Neurosurg Psychiatry 1999, 66:86-89.
242. Roggenkamper P., Jost W.H., Bihari K., et al. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006, 113:303-312.
243. Rubin A.D., Wodchis W.P., Spak C., et al. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II. Arch Otolaryngol Head Neck Surg 2004, 130:415-420.
244. Sankhla C., Lai E.C., Jankovic J. Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry 1998, 65:722-728.
245. Satija P., Ondo W.G. Cranial dystonia. Handbook of Dystonia 2007, Informa Healthcare, New York, NY. M. Stacy (Ed.).
246. Schmidt K.E., Linden D.E., Goebel R., et al. Striatal activation during blepharospasm revealed by fMRI. Neurology 2003, 60:1738-1743.
247. Schneider S.A., Bhatia K.P. The entity of jaw tremor and dystonia. Mov Disord 2007, 22:1491-1495.
248. Schneider S.A., Aggarwal A., Bhatt M., et al. Severe tongue protrusion dystonia: clinical syndromes and possible treatment. Neurology 2006, 67:940-943.
249. Schramm A., Classen J., Reiners K., et al. Characteristics of sensory trick-like manoeuvres in jaw-opening dystonia. Mov Disord 2007, 22:430-433.
250. Scolding N.J., Smith S.M., Sturman S., et al. Auctioneer's jaw: a case of occupational oromandibular hemidystonia. Mov Disord 1995, 10:508-509.
251. Scott A.B., Kennedy R.A., Stubbs H.A. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 1985, 103:347-350.
252. Sforza E., Montagna P., Defazio G., et al. Sleep and cranial dystonia. Electroencephalogr Clin Neurophysiol 1991, 79:166-169.
253. Sheehy M.P., Marsden C.D. Writers' cramp-a focal dystonia. Brain 1982, 105:461-480.
254. Sieberer M.G., Vieregge P., Klein C., et al. Concordant late onset of craniocervical dystonia in a pair of monozygotic twins. Mov Disord 1999, 14:1040-1043.
255. Siebner H.R., Tormos J.M., Ceballos-Baumann A.O., et al. Low-frequency repetitive transcranial magnetic stimulation of the motor cortex in writer's cramp. Neurology 1999, 52:529-537.
256. Simpson D.M., Blitzer A., Brashear A., et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1699-1706.
257. Singer C., Papapetropoulos S. A comparison of jaw-closing and jaw-opening idiopathic oromandibular dystonia. Parkinsonism Relat Disord 2006, 12:115-118.
258. Singer C., Velickovic M. Cervical dystonia: etiology and pathophysiology. Neurol Clin 2008, 26:9-22.
259. Smith M.E., Ford C.N. Resistance to botulinum toxin injections for spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2000, 126:533-535.
260. Sohn Y.H., Hallett M. Disturbed surround inhibition in focal hand dystonia. Ann Neurol 2004, 56:595-599.
261. Sohtaoglu M., Ergin H., Ozekmekci S., et al. Patient with late-onset Wilson's disease: deterioration with penicillamine. Mov Disord 2007, 22:290-291.
262. Spivak B., Gonen N., Mester R., et al. Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents. Int Clin Psychopharmacol 1996, 11:207-209.
263. Stacy M. Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin 2008, 26:23-42.
264. Suchowersky O., Calne D.B. Non-dystonic causes of torticollis. Adv Neurol 1988, 50:501-508.
265. Sveinbjornsdottir S., Pakkenberg H., Werdelin L. Developmental stuttering followed by intermittent jaw opening dystonia. Mov Disord 1993, 8:396-397.
266. Taira T., Kobayashi T., Takahashi K., et al. A new denervation procedure for idiopathic cervical dystonia. J Neurosurg 2002, 97:201-206.
267. Taira T., Harashima S., Hori T. Neurosurgical treatment for writer's cramp. Acta Neurochir Suppl 2003, 87:129-131.
268. Tan E.K., Chan L.L. Sensory tricks and treatment in primary lingual dystonia. Mov Disord 2005, 20:388.
269. Tan E.K., Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 1999, 53:2102-2107.
270. Tan E.K., Jankovic J. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry 2000, 68:186-190.
271. Tarlov E. On the problem of the pathology of spasmodic torticollis in man. J Neurol Neurosurg Psychiatry 1970, 33:457-463.
272. Tas N., Karatas G.K., Sepici V. Hand orthosis as a writing aid in writer's cramp. Mov Disord 2001, 16:1185-1189.
273. Tempel L.W., Perlmutter J.S. Abnormal cortical responses in patients with writer's cramp. Neurology 1993, 43:2252-2257.
274. Thickbroom G.W., Byrnes M.L., Stell R., et al. Reversible reorganisation of the motor cortical representation of the hand in cervical dystonia. Mov Disord 2003, 18:395-402.
275. Thomas M., Jankovic J. Psychogenic movement disorders: diagnosis and management. CNS Drugs 2004, 18:437-452.
276. Thompson P.D., Obeso J.A., Delgado G., et al. Focal dystonia of the jaw and the differential diagnosis of unilateral jaw and masticatory spasm. J Neurol Neurosurg Psychiatry 1986, 49:651-656.
277. Tinazzi M., Farina S., Bhatia K., et al. TENS for the treatment of writer's cramp dystonia: a randomized, placebo-controlled study. Neurology 2005, 64:1946-1948.
278. Tolosa E., Marti M.J. Blepharospasm-oromandibular dystonia syndrome (Meige's syndrome): clinical aspects. Adv Neurol 1988, 49:73-84.
279. Tolosa E., Kulisevsky J., Fahn S. Meige syndrome: primary and secondary forms. Adv Neurol 1988, 50:509-515.
280. Tolosa E.S., Klawans H.L. Meiges disease: a clinical form of facial convulsion, bilateral and medial. Arch Neurol 1979, 36:635-637.
281. Truong D., Duane D.D., Jankovic J., et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005, 20:783-791.
282. Truong D., Comella C., Fernandez H.H., et al. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 2008, 14:407-414.
283. Truong D.D., Rontal M., Rolnick M., et al. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 1991, 101:630-634.
284. Tsui J.K., Eisen A., Mak E., et al. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 1985, 12:314-316.
285. Tsui J.K., Bhatt M., Calne S., et al. Botulinum toxin in the treatment of writer's cramp: a double-blind study. Neurology 1993, 43:183-185.
286. Vagefi M.R., Lin C.C., Mccann J.D., et al. Exacerbation of blepharospasm associated with craniocervical dystonia after placement of bilateral globus pallidus internus deep brain stimulator. Mov Disord 2008, 23:454-456.
287. Van Den Bergh P., Francart J., Mourin S., et al. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 1995, 18:720-729.
288. Van Hilten J.J., Geraedts E.J., Marinus J. Peripheral trauma and movement disorders. Parkinsonism Relat Disord 2007, 13:S395-S399.
289. Vidailhet M., Vercueil L., Houeto J.L., et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005, 352:459-467.
290. Vitek J.L. Surgery for dystonia. Neurosurg Clin N Am 1998, 9:345-366.
291. Waters C.H., Faust P.L., Powers J., et al. Neuropathology of lubag (x-linked dystonia parkinsonism). Mov Disord 1993, 8:387-390.
292. Weiner W.J. Can peripheral trauma induce dystonia? No!. Mov Disord 2001, 16:13-22.
293. Weiss E.M., Hershey T., Karimi M., et al. Relative risk of spread of symptoms among the focal onset primary dystonias. Mov Disord 2006, 21:1175-1181.
294. Wenning G.K., Kiechl S., Seppi K., et al. Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. Lancet Neurol 2005, 4:815-820.
295. Wohlfarth K., Muller C., Sassin I., et al. Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin Neuropharmacol 2007, 30:86-94.
296. Yianni J., Bain P., Giladi N., et al. Globus pallidus internus deep brain stimulation for dystonic conditions: a prospective audit. Mov Disord 2003, 18:436-442.
297. Yianni J., Bain P.G., Gregory R.P., et al. Post-operative progress of dystonia patients following globus pallidus internus deep brain stimulation. Eur J Neurol 2003, 10:239-247.
298. Yoshimura D.M., Aminoff M.J., Olney R.K. Botulinum toxin therapy for limb dystonias. Neurology 1992, 42:627-630.
299. Yoshor D., Hamilton W.J., Ondo W., et al. Comparison of thalamotomy and pallidotomy for the treatment of dystonia. Neurosurgery 2001, 48:818-824. discussion 824-826.
300. Zadro I., Brinar V.V., Barun B., et al. Cervical dystonia due to cerebellar stroke. Mov Disord 2008, 23:919-920.
301. Zeuner K.E., Hallett M. Sensory training as treatment for focal hand dystonia: a 1-year follow-up. Mov Disord 2003, 18:1044-1047.
302. Zweig R.M., Hedreen J.C., Jankel W.R., et al. Pathology in brainstem regions of individuals with primary dystonia. Neurology 1988, 38:702-776.